Genix Pharmaceuticals Corporation focuses on formulating, manufacturing, and marketing nutraceuticals and pharmaceuticals in Canada, including its product Flu-X. The company faces significant concerns, notably a negative return on assets of -124.7% and a very low current ratio of 0.03, indicating liquidity issues. These financial metrics raise red flags about operational efficiency and financial stability. While the market cap is modest at $1.22M, the lack of positive performance metrics suggests challenges ahead for growth and sustainability.
Loading financial metrics...
Company has $4K in cash but burned $19K last quarter. At this burn rate, only 0.2 quarters of runway remain without additional financing.
Company posted a loss of $-159K over the last year, representing Infinity% of revenue.
Debt of $965K is 224.4x the company's cash position of $4K.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (April 30, 2025)